Browse the evidence

Exercise and insulin stimulate glucose uptake via distinct, independent signaling pathways that both converge on GLUT4 translocation.

Exercise improves blood sugar control through mechanisms that are separate from insulin. This means exercise can be beneficial even for those with severe insulin resistance, as it bypasses some of the defective insulin signaling pathways.

Pharmacological inhibition of DPP-4 improves glycemic control in Type 2 Diabetes by preventing the degradation of endogenous incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon.

DPP-4 inhibitors (like vildagliptin, sitagliptin) are oral medications that help your body manage blood sugar more effectively by keeping your natural 'incretin' hormones (GLP-1 and GIP) active longer. They are safe, well-tolerated, and do not typically cause low blood sugar on their own. They work best when your blood sugar is high, stimulating insulin only when needed.

Automated insulin delivery (AID) systems significantly improve glycemic control in people with type 1 diabetes by increasing time in range and reducing hypoglycemia compared to other therapies.

If you have Type 1 Diabetes, an Automated Insulin Delivery (AID) system is a highly effective tool to improve your blood sugar control. It automatically adjusts your insulin based on real-time glucose readings, helping you spend more time in your target range and less time in dangerous low or high states. While it still requires you to count carbs and announce meals, the system handles the fine-tuning. Ensure you receive proper training and support from your healthcare provider to get the most benefit and address any access barriers.

Obesity and weight gain exacerbate insulin resistance in PCOS by selectively impairing the PI3-K pathway while leaving the MAP-K pathway intact, leading to compensatory hyperinsulinemia and hyperandrogenism.

Understanding that weight gain worsens the hormonal imbalance in PCOS through specific insulin pathway defects can help patients see why weight management is critical for symptom control, not just appearance.

Insulin resistance (IR) is a major driver of PCOS pathophysiology, present in 65-95% of women with PCOS, and is independent of and exacerbated by obesity.

Insulin resistance is a core feature of PCOS, affecting most women with the condition, regardless of weight. Managing insulin levels is crucial for treating PCOS symptoms and reducing long-term health risks like type 2 diabetes.

Obesity is the primary environmental factor driving insulin resistance and the pathogenesis of Type 2 Diabetes (T2D) through mechanisms involving visceral fat distribution, ectopic lipid deposition, and gut microbiome dysbiosis.

Focus on reducing visceral and ectopic fat through sustainable lifestyle changes, as this is the most effective way to improve insulin sensitivity and prevent Type 2 Diabetes. Prioritize weight management, especially in high-risk groups, as it is the primary driver of the disease.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

Activation of the melanocortin-4 receptor (MC4R) by alpha-melanocyte-stimulating hormone (alpha-MSH) decreases energy intake and increases energy expenditure.

Your brain uses a specific hormonal pathway (leptin/insulin -> POMC -> MC4R) to regulate hunger and energy use. When this system works, it helps you stop eating and burn energy. Disruptions in this pathway (due to genetics or obesity) can make this harder, but the mechanism itself is a valid target for understanding appetite control.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are proven to significantly lower your risk of heart attack, stroke, and death. This benefit exists alongside blood sugar control. However, if you have heart failure with reduced ejection fraction, these drugs may increase risks, so discuss your specific heart condition with your doctor before starting.

Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.

Semaglutide is safe for your heart. Large studies have shown it does not increase the risk of heart attack, stroke, or cardiovascular death in people with type 2 diabetes, and may even offer benefits.

Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.

Unlike insulin, Tirzepatide does not increase the risk of low blood sugar (hypoglycemia) when used alone. In fact, it has a lower risk of causing hypoglycemia compared to basal insulin. This makes it a safer option for patients who are concerned about blood sugar lows.

SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular benefits (reduced MACE and heart failure hospitalization) and slow kidney disease progression, distinct from older glucose-lowering drugs.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga) or GLP-1 agonists (like Ozempic, Trulicity). These drugs protect your heart and kidneys beyond just lowering sugar, unlike older diabetes medications.

Bariatric surgery resolves obesity-associated gonadal dysfunction (PCOS in women, MOSH in men) in the vast majority of severely obese patients, with resolution rates of 96% for PCOS and 87% for MOSH.

If you are severely obese and have been diagnosed with PCOS or Male Obesity-Associated Secondary Hypogonadism (MOSH), bariatric surgery is the most effective treatment for resolving these conditions. Unlike diet or medication which often only manage symptoms, surgery addresses the underlying metabolic drivers, leading to resolution in nearly all women with PCOS and most men with MOSH. Consult a bariatric specialist to see if you are a candidate.

Bariatric surgery reverses the sex-specific hormonal imbalances caused by obesity: it increases testosterone in men and decreases testosterone in women, while increasing SHBG and decreasing estradiol in both.

Bariatric surgery normalizes sex hormones in a sex-specific way. Men typically see their testosterone levels rise to normal ranges, while women see their elevated testosterone levels drop. Both groups see an increase in Sex Hormone Binding Globulin (SHBG) and a decrease in Estradiol. This hormonal normalization is key to resolving fertility and sexual health issues associated with obesity.

Obesity-associated gonadal dysfunction is highly prevalent in severely obese patients, affecting 36% of women (PCOS) and 64% of men (MOSH).

If you are severely obese, you are at high risk for hormonal reproductive issues. About 1 in 3 severely obese women has PCOS, and nearly 2 in 3 severely obese men has low testosterone (MOSH). Screening for these conditions is recommended during initial diagnostic workup for severe obesity.

Women with diabetes face a 58% greater risk of coronary heart disease (CHD) mortality and a 13% greater risk of all-cause mortality compared to men with diabetes, indicating a significant sex-specific disparity in cardiovascular outcomes.

If you are a woman with diabetes, your risk of dying from heart disease is significantly higher than a man with diabetes. This means you should not just manage your blood sugar, but actively prioritize cardiovascular health with your doctor, potentially requiring more aggressive monitoring or prevention strategies than standard male-centric guidelines might suggest.

Metformin administration (1,700 mg/day) blunts gains in lean body mass and thigh muscle mass in older adults undergoing progressive resistance training.

If you are over 65 and taking metformin, expect less muscle gain from resistance training compared to someone not taking it. This is likely due to how metformin affects cellular signaling (mTOR/AMPK). Do not stop your medication without medical advice, but adjust your expectations for muscle growth.

Once-weekly subcutaneous semaglutide 2.4 mg reduces the risk of major kidney composite endpoints (including macroalbuminuria and persistent eGFR decline) in patients with overweight/obesity and established cardiovascular disease, regardless of diabetes status.

If you have obesity and heart disease but no diabetes, semaglutide 2.4mg weekly offers significant kidney protection. It reduces the risk of serious kidney events like needing dialysis or developing heavy protein in the urine. While there is a temporary initial dip in kidney filtration numbers, long-term outcomes are better than placebo. This is a standard-of-care option for kidney risk reduction in this specific high-risk group.

Semaglutide 2.4 mg slows the rate of eGFR decline and reduces albuminuria (UACR) in patients with overweight/obesity, with greater benefits observed in those with baseline eGFR <60 ml/min/1.73m².

For patients with existing kidney impairment (eGFR <60), semaglutide not only slows further decline but may actually improve eGFR readings compared to placebo. It also significantly reduces albuminuria (protein in urine), a key marker of kidney stress. This benefit is consistent across subgroups.

Bariatric surgery (RYGB/VSG) provides superior sustained weight loss (13-27%) and T2D remission compared to pharmacological interventions, largely driven by endocrine changes rather than just mechanical restriction.

Bariatric surgery (like gastric bypass) is currently the most effective treatment for obesity, achieving 13-27% sustained weight loss and often curing type 2 diabetes. Its success is driven by hormonal changes (increased GLP-1/PYY) rather than just stomach size reduction. However, due to its invasive nature, it is reserved for extreme cases, driving the need for drugs that can mimic these hormonal effects.

Statins reduce cardiovascular events and inflammatory markers (CRP) but may increase the risk of new-onset diabetes, indicating a trade-off between cardiovascular protection and glycemic control.

Statins are highly effective at preventing heart attacks and strokes, even in people with normal cholesterol but high inflammation. However, they can slightly increase the risk of developing diabetes. For most people with cardiovascular risk, the heart protection outweighs this risk. Monitor your blood sugar if you start statins.

Melatonin regulates circadian rhythms and sleep-wake cycles by acting on the suprachiasmatic nucleus (SCN) and pineal gland, with secretion peaking at night.

Melatonin is your body's natural signal for darkness and sleep. It is produced by the pineal gland in response to darkness, peaks at night, and helps regulate your sleep-wake cycle. Exposure to light at night suppresses this natural production.

Tirzepatide treatment is associated with a higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting) compared to placebo and insulin, and slightly higher than GLP-1 RAs, though serious adverse events are not significantly different from placebo.

Expect gastrointestinal side effects like nausea, diarrhea, or vomiting, especially when starting or increasing the dose. These are usually mild and go away. Serious side effects (like pancreatitis or heart issues) did not show a statistically significant increase compared to placebo in this analysis. Monitor your symptoms and report severe or persistent issues to your doctor.

Tirzepatide use is associated with a significantly higher incidence of gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, compared to placebo, although serious adverse event rates remain comparable.

Expect gastrointestinal side effects when starting tirzepatide. Nausea, vomiting, and diarrhea are significantly more common than with a placebo, particularly when starting or increasing the dose. However, these are typically mild to moderate and do not appear to increase the risk of serious health events. Most patients tolerate the medication well enough to continue treatment, which is necessary to achieve the significant weight loss benefits.